Department of Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Critical Care Medicine, The Sixth Affiliated Hospital of Harbin Medical University, Harbin, China.
Front Immunol. 2022 Sep 23;13:957407. doi: 10.3389/fimmu.2022.957407. eCollection 2022.
In this study, we aimed to explore whether lymphocyte-C-reactive protein ratio (LCR) can differentiate disease severity of coronavirus disease 2019 (COVID-19) patients and its value as an assistant screening tool for admission to hospital and intensive care unit (ICU). A total of 184 adult COVID-19 patients from the COVID-19 Treatment Center in Heilongjiang Province at the First Affiliated Hospital of Harbin Medical University between January 2020 and March 2021 were included in this study. Patients were divided into asymptomatic infection group, mild group, moderate group, severe group, and critical group according to the Diagnosis and Treatment of New Coronavirus Pneumonia (ninth edition). Demographic and clinical data including gender, age, comorbidities, severity of COVID-19, white blood cell count (WBC), neutrophil proportion (NEUT%), lymphocyte count (LYMPH), lymphocyte percentage (LYM%), red blood cell distribution width (RDW), platelet (PLT), C-reactive protein (CRP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (SCr), albumin (ALB), total bilirubin (TB), direct bilirubin (DBIL), indirect bilirubin (IBIL), and D-dimer were obtained and collated from medical records at admission, from which sequential organ failure assessment (SOFA) score and LCR were calculated, and all the above indicators were compared among the groups. Multiple clinical parameters, including LYMPH, CRP, and LCR, showed significant differences among the groups. The related factors to classify COVID-19 patients into moderate, severe, and critical groups included age, number of comorbidities, WBC, LCR, and AST. Among these factors, the number of comorbidities showed the greatest effect, and only WBC and LCR were protective factors. The area under the receiver operating characteristic (ROC) curve of LCR to classify COVID-19 patients into moderate, severe, and critical groups was 0.176. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 1,780.7050 and 84.6% and 66.2%, respectively. The related factors to classify COVID-19 patients into severe and critical groups included the number of comorbidities, PLT, LCR, and SOFA score. Among these factors, SOFA score showed the greatest effect, and LCR was the only protective factor. The area under the ROC curve of LCR to classify COVID-19 patients into severe and critical groups was 0.106. The cutoff value of LCR and the sensitivity and specificity of the ROC curve were 571.2200 and 81.3% and 90.0%, respectively. In summary, LCR can differentiate disease severity of COVID-19 patients and serve as a simple and objective assistant screening tool for hospital and ICU admission.
在这项研究中,我们旨在探讨淋巴细胞- C 反应蛋白比值(LCR)是否可以区分 2019 年冠状病毒病(COVID-19)患者的疾病严重程度,以及其作为住院和重症监护病房(ICU)入院辅助筛查工具的价值。共纳入了 2020 年 1 月至 2021 年 3 月期间哈尔滨医科大学附属第一医院 COVID-19 治疗中心的 184 例成年 COVID-19 患者。根据《新型冠状病毒肺炎诊疗方案(第九版)》,患者根据无症状感染组、轻症组、普通组、重症组和危重组进行分组。从病历中获取并整理了包括性别、年龄、合并症、COVID-19 严重程度、白细胞计数(WBC)、中性粒细胞比例(NEUT%)、淋巴细胞计数(LYMPH)、淋巴细胞百分比(LYM%)、红细胞分布宽度(RDW)、血小板(PLT)、C 反应蛋白(CRP)、丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)、血清肌酐(SCr)、白蛋白(ALB)、总胆红素(TB)、直接胆红素(DBIL)、间接胆红素(IBIL)和 D-二聚体等人口统计学和临床数据,并计算了序贯器官衰竭评估(SOFA)评分和 LCR,比较了各组之间的所有上述指标。多个临床参数,包括 LYMPH、CRP 和 LCR,在各组之间存在显著差异。将 COVID-19 患者分为中度、重度和危重组的相关因素包括年龄、合并症数量、WBC、LCR 和 AST。在这些因素中,合并症数量的影响最大,只有 WBC 和 LCR 是保护因素。LCR 对 COVID-19 患者进行中度、重度和危重组分类的受试者工作特征(ROC)曲线下面积为 0.176。LCR 的截断值和 ROC 曲线的灵敏度和特异性分别为 1,780.7050 和 84.6%和 66.2%。将 COVID-19 患者分为重度和危重组的相关因素包括合并症数量、PLT、LCR 和 SOFA 评分。在这些因素中,SOFA 评分的影响最大,LCR 是唯一的保护因素。LCR 对 COVID-19 患者进行重度和危重组分类的 ROC 曲线下面积为 0.106。LCR 的截断值和 ROC 曲线的灵敏度和特异性分别为 571.2200 和 81.3%和 90.0%。总之,LCR 可以区分 COVID-19 患者的疾病严重程度,并可作为住院和 ICU 入院的简单客观辅助筛查工具。